Clinical Trial Update: CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer

View source ↗

Summary

An ongoing clinical trial is evaluating circulating tumor DNA as a biomarker of treatment efficacy in patients with high-grade serous ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Serous Ovarian Cancer

Snippet

Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: High-grade Serous Ovarian Cancer, Circulating Tumor DNA | Status: RECRUITING